Seven Of Nine
Risk/Reward
- Registrato
- 12/6/07
- Messaggi
- 8.249
- Punti reazioni
- 441
Apro un thread su questo gigante farmaceutico visto che l'ultimo era un po' datato. 
Oggi è uscita la trimestrale, non malvagia, ma sotto le attese.
Novartis Profit Misses Analyst Estimates, Shares Drop
Jan. 28 (Bloomberg) -- Novartis AG’s fourth-quarter profit missed analysts’ estimates, sending the Swiss drugmaker’s shares to their lowest level in more than three months.
Net income rose to $1.5 billion, or 68 cents a share, from $904 million, or 40 cents, a year earlier, the Basel, Switzerland-based company said. Product withdrawals and generic-drug competition had depressed earnings a year ago. Sales were little changed overall, while drug revenue increased 5 percent. Novartis shares fell as much as 4.3 percent.
“The pharma unit didn’t deliver,” said Joerg De Vries- Hippen, chief investment officer in European equities at Allianz Global Investors in Frankfurt. “Pharma is supposed to be a safe haven in the current environment.”
Chief Executive Officer Daniel Vasella has cut jobs and reined in spending as Novartis prepares for the patent expiration on its hypertension drug Diovan. Europe’s fourth- largest drugmaker reduced its dependence on prescription medicines by developing its own generic treatments and vaccines and acquiring a stake in eye-care company Alcon Inc. last year.
Profit from continuing operations last quarter was $1.51 billion, falling short of the $1.78 billion median estimate of seven analysts surveyed by Bloomberg News.
Drug Mergers
Novartis fell 1.97 francs, or 3.8 percent, to 49.48 Swiss francs at 9:31 a.m. in Zurich trading. The drugmaker’s shares fell 10 percent in 2008, making it the eighth-worst-performing stock on the Bloomberg Europe Pharmaceutical Index.
A year ago, earnings were held back by generic competition and product withdrawals. Sales of five products, including the Famvir herpes medicine and the irritable bowel treatment Zelnorm had fallen by almost half to $1.7 billion from 2006 after the medicines either faced generic competition or were pulled from the market.
Vasella said Novartis will continue to make small acquisitions but probably won’t take part in a bigger wave of industry mergers.
“The most important thing is to grow organically,” he said in a televised interview. “But you have to act with your eyes wide open” after Pfizer Inc.’s $68 billion bid for Wyeth earlier this week. He said he doesn’t view the enlarged Pfizer as a competitive threat.
This year at Novartis, sales from continuing operations will probably rise at a mid-single-digit rate this year. Drug sales will likely grow at a mid-to-high-single-digit rate in local currencies, Novartis said.
The company’s experimental drug for multiple sclerosis fingolimod, a pill aimed at making treatment less painful for patients, is still expected for submission to regulators at the end of 2009, Novartis said.
The Swiss drugmaker is preparing for generic competition in 2012 with a clutch of new drugs including several combination heart pills and the Afinitor cancer drug.
Q4 Results Snapshot:
Grafico a 5 anni in dollari visto che la presentazioni di Novartis usano l'USD.
Io dico di monitorarla e aspettarla, perchè i flussi di cassa della società sono consistenti, finanziariamente è forte, i margini sono alti e il business è anticiclico. I rischi sono principalmente: Difficoltà nel recuperare i ricavi del Diovan il cui patent scade nel 2012, concorrenza dei generici, possibili future acquisizioni che potrebbero aver un impatto negativo nel breve termine per gli azionisti Novartis.
Oggi è uscita la trimestrale, non malvagia, ma sotto le attese.
Novartis Profit Misses Analyst Estimates, Shares Drop
Jan. 28 (Bloomberg) -- Novartis AG’s fourth-quarter profit missed analysts’ estimates, sending the Swiss drugmaker’s shares to their lowest level in more than three months.
Net income rose to $1.5 billion, or 68 cents a share, from $904 million, or 40 cents, a year earlier, the Basel, Switzerland-based company said. Product withdrawals and generic-drug competition had depressed earnings a year ago. Sales were little changed overall, while drug revenue increased 5 percent. Novartis shares fell as much as 4.3 percent.
“The pharma unit didn’t deliver,” said Joerg De Vries- Hippen, chief investment officer in European equities at Allianz Global Investors in Frankfurt. “Pharma is supposed to be a safe haven in the current environment.”
Chief Executive Officer Daniel Vasella has cut jobs and reined in spending as Novartis prepares for the patent expiration on its hypertension drug Diovan. Europe’s fourth- largest drugmaker reduced its dependence on prescription medicines by developing its own generic treatments and vaccines and acquiring a stake in eye-care company Alcon Inc. last year.
Profit from continuing operations last quarter was $1.51 billion, falling short of the $1.78 billion median estimate of seven analysts surveyed by Bloomberg News.
Drug Mergers
Novartis fell 1.97 francs, or 3.8 percent, to 49.48 Swiss francs at 9:31 a.m. in Zurich trading. The drugmaker’s shares fell 10 percent in 2008, making it the eighth-worst-performing stock on the Bloomberg Europe Pharmaceutical Index.
A year ago, earnings were held back by generic competition and product withdrawals. Sales of five products, including the Famvir herpes medicine and the irritable bowel treatment Zelnorm had fallen by almost half to $1.7 billion from 2006 after the medicines either faced generic competition or were pulled from the market.
Vasella said Novartis will continue to make small acquisitions but probably won’t take part in a bigger wave of industry mergers.
“The most important thing is to grow organically,” he said in a televised interview. “But you have to act with your eyes wide open” after Pfizer Inc.’s $68 billion bid for Wyeth earlier this week. He said he doesn’t view the enlarged Pfizer as a competitive threat.
This year at Novartis, sales from continuing operations will probably rise at a mid-single-digit rate this year. Drug sales will likely grow at a mid-to-high-single-digit rate in local currencies, Novartis said.
The company’s experimental drug for multiple sclerosis fingolimod, a pill aimed at making treatment less painful for patients, is still expected for submission to regulators at the end of 2009, Novartis said.
The Swiss drugmaker is preparing for generic competition in 2012 with a clutch of new drugs including several combination heart pills and the Afinitor cancer drug.
Q4 Results Snapshot:
Grafico a 5 anni in dollari visto che la presentazioni di Novartis usano l'USD.
Io dico di monitorarla e aspettarla, perchè i flussi di cassa della società sono consistenti, finanziariamente è forte, i margini sono alti e il business è anticiclico. I rischi sono principalmente: Difficoltà nel recuperare i ricavi del Diovan il cui patent scade nel 2012, concorrenza dei generici, possibili future acquisizioni che potrebbero aver un impatto negativo nel breve termine per gli azionisti Novartis.
